Investment Managers Series Trus (IREX)

Key Updates

IREX advanced 2.30% since the 20 September report, rising from $17.64 to $18.05, extending the rebound that began at the $14.79 low recorded on 15 September. The fund is now up 22.05% from that low over four trading sessions, though it remains down 40.56% year-to-date. Two new news events were recorded since the last report, both related to the broader leveraged ETF ecosystem rather than IREX-specific fundamentals. The recent price action suggests continued momentum for the recovery, but the fund remains deep in negative territory for the year.

Current Trend

IREX has established a clear short-term uptrend since the 15 September low of $14.79, with successive gains of 3.85%, 10.61%, 3.83%, and now 2.30% over the four most recent reporting periods. The price has moved from $14.79 to $18.05, representing a 22.05% recovery. However, the longer-term trend remains firmly bearish: the fund is down 40.56% year-to-date and 31.67% over the past six months. The 5-day gain of 18.95% and 1-month gain of 18.33% indicate that the recent recovery has been substantial, but these gains only partially offset the steep decline experienced earlier in the year. The immediate resistance level appears to be near the $18.05 current price, with the next potential resistance around the $18.50–$19.00 zone based on the trajectory of the recent rebound. Support is established at the $16.99 level from the 18 September close, with stronger support at the $14.79 low from 15 September.

Investment Thesis

IREX is an investment product within the Investment Managers Series Trust, and the available news data does not provide direct information about the fund's underlying holdings, sector allocation, or specific investment objective. The investment thesis must therefore be constructed primarily from the price action data and the broader market context provided by the news articles. The fund's steep year-to-date decline of 40.56% suggests significant exposure to sectors or assets that have experienced substantial drawdowns in 2026. The recent recovery, however, indicates that the fund may be rebounding alongside broader market sentiment. The news flow surrounding leveraged ETF launches—including products tied to AI-related companies such as Anthropic, SK Hynix, and the MANGOS+ index—suggests that the market is actively expanding derivative-based exposure to technology and AI-focused assets, which may be relevant to IREX if it holds similar exposures. However, without specific fund composition data, the thesis must remain general and focus on the observable price dynamics and the leveraged ETF ecosystem context.

Thesis Status

The investment thesis status has modestly improved since the last report. The fund has now recorded four consecutive positive reporting periods, with the 2.30% gain today continuing the recovery pattern. The price has moved from the 15 September low of $14.79 to $18.05, a recovery of 22.05%, which suggests that buying pressure has been sustained. However, the thesis remains cautious: the fund is still down 40.56% year-to-date, and the current price remains well below levels seen earlier in the year. The recovery has been sharp but has not yet demonstrated that it can reverse the longer-term downtrend. The absence of IREX-specific news means that the recovery is likely driven by broader market factors or sector rotation rather than fund-specific catalysts. The thesis status is therefore "recovering but unconfirmed"—the short-term momentum is positive, but the sustainability of the rebound is not yet established.

Key Drivers

The primary driver of IREX's recent price action appears to be broader market dynamics rather than fund-specific news, as no IREX-specific announcements were included in the provided news data. The news flow continues to be dominated by the leveraged ETF product expansion, which reflects strong investor demand for amplified exposure to high-volatility assets. Notable developments include:

• Yorkville America launched the 2X Inverse MANGOS Plus Daily Target ETF (MNGB) on 21 September, the same day as the current report, indicating continued product innovation in the leveraged space (Source).
• Jane Street Group entered the market for swaps tied to leveraged ETFs, providing approximately $1.2 billion notional in the second quarter, which signals growing institutional participation in this segment (Source).
• Multiple asset managers (Leverage Shares, Tradr, Direxion) have filed for leveraged and inverse ETFs tied to Anthropic ahead of its anticipated IPO, reflecting strong market interest in AI-related exposure (Source, Source, Source).
• BMO and REX Shares continued to expand their MicroSectors platform with new leveraged ETNs across Communication Services, Consumer Staples, and AI-focused indices (Source, Source).

These drivers suggest that the leveraged ETF ecosystem is expanding rapidly, with a particular focus on AI and technology-related underlying assets. If IREX holds exposure to similar sectors, the increased market attention could support demand for the fund's underlying holdings.

Technical Analysis

IREX is trading at $18.05, up 2.30% on the day. The price action shows a clear V-shaped recovery pattern from the 15 September low of $14.79. The fund has recorded gains in four consecutive reporting periods: +3.85% (16 Sep), +10.61% (18 Sep), +3.83% (20 Sep), and +2.30% (21 Sep). The 5-day gain of 18.95% and 1-month gain of 18.33% confirm that the recovery has been substantial and sustained. However, the 6-month decline of 31.67% and year-to-date decline of 40.56% indicate that the fund remains in a deeply bearish longer-term trend. The current price of $18.05 is approaching the $18.50–$19.00 zone, which may act as resistance based on the trajectory of the rebound. The $16.99 level from the 18 September close serves as near-term support, with the $14.79 low as the critical support level. The momentum is clearly positive in the short term, but the fund has not yet recovered to levels that would suggest a reversal of the primary downtrend. The immediate price action suggests that the recovery could continue, but the magnitude of the year-to-date decline warrants caution.

Bull Case

• The fund has recorded four consecutive positive reporting periods, with a cumulative gain of 22.05% from the 15 September low of $14.79, demonstrating sustained buying momentum and a clear short-term uptrend.
• The 5-day gain of 18.95% and 1-month gain of 18.33% indicate that the recovery is accelerating, suggesting that investor sentiment toward the fund's underlying assets may be improving.
• The rapid expansion of leveraged ETF products tied to AI-related companies (Anthropic, SK Hynix, MANGOS+ index) reflects strong market demand for technology and AI exposure, which could benefit IREX if it holds similar positions (Source, Source).
• Jane Street's entry into the leveraged ETF swaps market with $1.2 billion notional signals growing institutional interest in leveraged products, which could increase liquidity and market efficiency for funds like IREX (Source).
• The continued product innovation in the leveraged ETF space, including new launches from Yorkville America and BMO/REX Shares, indicates that asset managers see sustained demand for amplified market exposure, which may reflect overall market confidence (Source, Source).

Bear Case

• IREX remains down 40.56% year-to-date and 31.67% over the past six months, indicating that the fund has experienced a severe and sustained decline that the recent recovery has only partially offset.
• The recent gains, while substantial in percentage terms, have occurred from a deeply depressed price level, and the fund remains well below its levels from earlier in the year, suggesting that the recovery may be a technical bounce rather than a fundamental reversal.
• No IREX-specific positive news has been reported, meaning the recovery is driven by broader market factors without confirmation of improving fundamentals for the fund's underlying holdings.
• The leveraged ETF products described in the news carry significant risks, including daily rebalancing, compounding decay, and potential total loss, and the proliferation of such products may indicate elevated market speculation rather than fundamental strength (Source, Source).
• The fund's 6-month decline of 31.67% suggests that the underlying assets have been under significant pressure, and the recent 18.95% 5-day gain may be vulnerable to profit-taking or reversal if the broader market sentiment shifts.